Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus

What Was Tested

This registered phase 2 trial tested Semaglutide.

Approximately 240 adults aged 18 to 75 years with type 2 diabetes mellitus will be enrolled.

It had six arms (groups): MWN109 Cohort 1 (experimental), MWN109 Cohort 2 (experimental), MWN109 Cohort 3 (experimental), MWN109 Cohort 4 (experimental) and Placebo (placebo comparator).

The registry classes the interventions as drug.

Who Took Part

The registry lists 240 planned participants were the target.

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Male or female participants aged 18 to 75 years (inclusive) at the time of signing the informed consent form. BMI ≥20.0 kg/m² and ≤40.0 kg/m² at screening.

The full record lists 6 inclusion and 17 exclusion criteria; among the exclusions: diagnosed or suspected type 1 diabetes mellitus, other specific types of diabetes mellitus (excluding gestational diabetes mellitus), or secondary diabetes mellitus; use of insulin within 1 year prior to randomization (except for acute short-term use of ≤14 days); diabetic ketoacidosis or hyperosmolar hyperglycemic state within 24 weeks prior to randomization.

How the Study Was Run

The set-up was randomized, parallel-group and double-blind.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.

Those kept unaware of assignments: participant and investigator.

It started in 2026-06-23 with completion listed for 2027-03.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 20 Compared to Placebo (time frame: Baseline, Week 20).

It also tracked 8 secondary outcomes, for example Change in HbA1c from Baseline at Week 20 Compared with Semaglutide Tablets and Change from baseline in HbA1c.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Semaglutide in 240 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.